Slingshot members are tracking this event:

Pfizer (PFE) initiates a Phase 3 open-label lead-in study evaluating current factor IX prophylaxis replacement therapy in the usual care setting for patients with hemophilia B

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The primary endpoint is change in annualized bleed rate from baseline over a six-month treatment period. According to, the estimated completion date is November 2020
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 16, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hemophilia B, Factor Ix